Sitryx Therapeutics plans to advance SYX-5219, an oral, targeted, disease-modifying anti-inflammatory therapy that targets pyruvate kinase M2 (PKM2), to the clinic.
Modulation of PKM2 alters B and T lymphocyte function and represents a novel therapeutic target with the potential to rebalance the immune system, normalize immune cell function and drive sustained disease remission in AD.
SYX-5219 will be Sitryx’s first candidate from its proprietary pipeline to progress to regulatory non-clinical studies to support a clinical trial authorization (CTA).
Regulatory submission preparation for SYX-5219 is underway, with clinical trials expected to commence in early 2025.
“The team has generated a strong preclinical data package that builds on the scientific community’s growing understanding of PKM2 and its role in the pathogenesis of atopic dermatitis,” says Lain Kilty, Chief Scientific Officer of Sitryx, in a news release. “These data have given us the confidence to move this program towards the clinic and we look forward to its continued progress.”
Ravi Rao, Chief Medical Officer of Sitryx, adds: “While newer therapies have moved beyond symptom control to include disease-modifying approaches, the condition continues to present a significant burden for patients and health systems. Sitryx is making great progress with its lead candidate, SYX-5219, an oral and novel targeted therapy with the potential to deliver significant benefit to patients.”
In January, the Company announced that Lilly, its partner in an exclusive global licensing and research collaboration, had commenced a Phase 1 study of itaconate mimetic (SYX-1042), a post-translational modification modulator program developed within the partnership.
